---
title: "Hoth Therapeutics, Inc. (HOTH.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/HOTH.US.md"
symbol: "HOTH.US"
name: "Hoth Therapeutics, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-19T23:44:07.907Z"
locales:
  - [en](https://longbridge.com/en/quote/HOTH.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/HOTH.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/HOTH.US.md)
---

# Hoth Therapeutics, Inc. (HOTH.US)

## Company Overview

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer’s or other neuroinflammatory diseases; and HT-004 for treatment of asthma and allergies using inhalational administration. The company is developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [oththerapeutics.com](https://oththerapeutics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.00 | 102 | - | - | - |
| PB | 2.82 | 105 | 2.15 | 1.88 | 1.52 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-25T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.60 |
| Highest Target | 5.00 |
| Lowest Target | 5.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/HOTH.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/HOTH.US/norm.md)
- [Related News](https://longbridge.com/en/quote/HOTH.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/HOTH.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**